Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Vaccinations01:51

Vaccinations

44.2K
Overview
44.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA DP/DRA molecule regulates systemic inflammation and neuroinflammation, aggravates cognitive impairment and long-term anxiety in murine model of sepsis-associated encephalopathy.

Frontiers in immunology·2026
Same author

Cardiac α2δ1 C-terminal contributes to left atrial hypertrophy in chronic ischemic heart failure, in association with changes in membrane GluN1 and p-CAMKII/p-HDAC4 signaling.

Cell and tissue research·2026
Same author

The Unseen and Positive Stereotypes: Portrayals of Older Adults in 100 Popular Chinese Films (2000-2024).

International journal of aging & human development·2026
Same author

Safety Assessment of <i>Eubacterium limosum</i> El1405 and Its Protective Effect Against <i>Salmonella</i> Typhimurium Infection in Mice.

Nutrients·2026
Same author

Normal kidney tissue derived extracellular vesicles suppress clear cell renal cell carcinoma progression via transfer their inhibitory miRNAs.

Cancer treatment and research communications·2026
Same author

Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction.

Biomedicines·2026

Related Experiment Video

Updated: Jun 13, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K

Unlocking Immunity: Innovative prostate cancer vaccine strategies.

Qiannan Gu1, Anning Qi2, Ne Wang3

  • 1China Pharmaceutical University, School of Basic Medicine and Clinical Pharmacy, Nanjing, Jiangsu 210009, China.

International Immunopharmacology
|September 14, 2024
PubMed
Summary

Cancer vaccines show promise for treating advanced prostate cancer (PCa) by overcoming tumor immunosuppression. Future research will refine vaccine design and combination therapies for better patient outcomes.

Keywords:
Combination therapyInnovative adjuvant and delivery modePersonalized medicineProstate cancer immunotherapyVaccine strategy

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Related Experiment Videos

Last Updated: Jun 13, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Prostate cancer (PCa) remains a significant cause of cancer mortality in men.
  • Current treatments for advanced or recurrent PCa are insufficient, highlighting an unmet clinical need.
  • The immunosuppressive tumor microenvironment in PCa limits the efficacy of conventional therapies.

Purpose of the Study:

  • To explore the potential of immunotherapy and cancer vaccines for advanced or recurrent prostate cancer.
  • To investigate strategies for overcoming the immunosuppressive tumor microenvironment in PCa.
  • To identify novel approaches for enhancing anti-tumor immune responses in prostate cancer.

Main Methods:

  • Review of preclinical and clinical studies on various cancer vaccine platforms.
  • Investigation of Dendritic Cell (DC) vaccines, DNA vaccines, mRNA vaccines, peptide vaccines, and viral vectors.
  • Exploration of combination therapies with immune checkpoint inhibitors and novel adjuvants.

Main Results:

  • Cancer vaccines targeting Tumor-Specific Antigens (TSA) and Tumor-Associated Antigens (TAA) show potential in PCa.
  • Various vaccine platforms (DC, DNA, mRNA, peptide, viral vectors) can elicit anti-tumor immune responses.
  • Novel strategies including combination therapies, adjuvants, and oral vaccines are being developed to improve efficacy.

Conclusions:

  • Cancer vaccines represent a promising therapeutic avenue for prostate cancer.
  • Optimizing vaccine design, combination strategies, and administration methods are key future directions.
  • Interdisciplinary collaboration and innovative clinical trials are crucial for advancing personalized PCa immunotherapy.